QurAlis Announces development Candidate for ALS Targeting STATHMIN-2 with the intent of pursuing STATEMIN-1
CAMBRIDGE, Mass., Sept. 14, 2021 -- QurAlis Corporation announced the nomination of QRL-201 as the Company's development candidate for ALS treatment. QRL-201 is currently undergoing a new drug-enabling study. It is based on patented techniques to restore STATHMIN-2 expression in ALS patients. QurAlis plans on starting clinical development for QRL-201 in the second half of 2022.
STATHMIN-2 is a well-known protein that is important for neural repair and achlorogenesis. It's important to develop specialized ALS patients and improve their sensitivity. QRL-201 rescues STMN2 in ALS patient-derived motor neuron disease models in the presence of TDP43 pathology. In addition to nearly all ALS patients, TDP43 pathology is associated with approximately 50 percent of patients with frontotemporal degeneration (FTD), the second most common form of dementia; about a third of Alzheimer's
"QRL-201 could potentially benefit ALS patients who have a loss of STMN2 due to TDP43 pathology, which could in turn slow disease progression," said Kasper Roet, PhD, CEO and co "We are excited to bring QRL-201 out of stealth and continue to advance our program to the clinic so we can quickly bring this potentially transformative treatment to patients."
A study using human neuronal stem cells from ALS patients found in 2019 that STMN2 is regulated by TDP43. The Eggan Lab showed that normal TDP43 functions are highly significant and can cause a huge decrease in expression of STMN2 and an impairment in neuronal repair which can be rescued by restoring SDMN2. These results were published in the newspaper. Nature Neuroscience .
Those who have a smear-like ALS are treated with the same type of therapy as the patient with l'incensis. Developed in the early 1990s, the patented discovery of Dr Human stem cell models understand the development of ALS in patients, identify precision medicine targets and test potential therapeutic molecules, said Dr. Roet.
QurAlis announced a second year of funding through Target ALS and The Association for Frontotemporal Degeneration to help the discovery of biomarkers and viable treatments for AIDS and FTD in collaboration with the University of
About QRL-201: about QR L-202:. QRL-201 is a therapeutic product for the recovery of STATHMIN-2 (STMN2) expression in amyotrophic lateral sclerosis (ALS) patients. STATHMIN-2 is a well-known protein that is important for sclerosis and liability, and therefore in the majority of ALS patients, expression of which is significantly decreased. STMN2 is a protein that is important for the recombination of microtubules, whose cytoskeleton is not inherited in xons. STATHMIN-2 is highly expressed in motor neurons, cells that degenerate mostly in patients suffering from ALS. In animal models, STMN2 deletion caused axonal degeneration, which is the primary functional deficit that causes paralysis in ALS patients.
About QurAlis Corporation, Inc. QurAlis is trailblazing the path of overcoming amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases with genetically validated targets with next-generation precision medicines. QurAlis' proprietary platforms and unique biomarkers enable the development and development of drugs that act directly on disease-causing genetic alterations. Founded by an internationally recognized team of neurodegenerative biologists from Harvard Medical School and Harvard University, QurAlis is advancing a wide pipeline of antisense oligonucleotides and small molecules to For more information, please visit www.quralis.com or follow us on Twitter @QurAlisCo.
SOURCE QurAlis QuerAlus is SURCE!
Links Related Related Links